Ceritinib (LDK378) prevents bone loss via suppressing Akt and NF-κB-induced osteoclast formation

BACKGROUND: Ceritinib is used for the treatment of patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC), who are at the risk of developing bone metastasis. During bone metastasis, tumor cells release factors that induce osteoclast formation, resulting in osteo...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Wenxin, Cao, Xiankun, Kong, Keyu, Rong, Kewei, Han, Shuai, Qin, An
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679281/
https://www.ncbi.nlm.nih.gov/pubmed/36425467
http://dx.doi.org/10.3389/fendo.2022.939959

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679281/
https://www.ncbi.nlm.nih.gov/pubmed/36425467
http://dx.doi.org/10.3389/fendo.2022.939959

Ejemplares similares